Menu
  • Join
  • Login
  • Contact
 

Search abstracts


EFFICACY AND SAFETY OF 12-WEEK LEDIPASVIR/SOFOSBUVIR IN PATIENTS WITH CHRONIC HEPATITIS C

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: LIU, Min-Li (E-Da Cancer Hospital, Department of Pharmacy, China Taiwan)
  • Co-author(s): Min-Li Liu: Department of Pharmacy, E-Da Cancer Hospital, Kaohsiung, China Taiwan
    Yung-Chia Hsu: Department of Pharmacy, E-Da Cancer Hospital, Kaohsiung, China Taiwan
    Yi-Ping Hsiang: Department of Pharmacy, E-Da Hospital, Kaohsiung, China Taiwan
  • Abstract:

    Background

    Direct-acting antiviral agents, including ledipasvir (LDV)/sofosbuvir (SOF), are now novel therapeutic agents for chronic hepatitis C (CHC). However, the efficacy and safety of these agents is not fully explored in Taiwan.

    Methods

    Patients with CHC receiving LDV/SOF 90 mg/400 mg with or without ribavirin for 12 weeks in our hospital from

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 21 September 2019

FIP Congresses